Transmission Properties of Atypical Creutzfeldt-Jakob Disease: a Clue to Disease Etiology?

Atsushi Kobayashi, a* Piero Parchi, b,c Masahito Yamada, d Paul Brown, e Daniela Saverioni, f Yuichi Matsuura, f Atsuko Takeuchi, f Shirou Mohri, g Tetsuyuki Kitamoto a

Department of Neurological Science, Tohoku University Graduate School of Medicine, Sendai, Japan; IRCCS, Istituto delle Scienze Neurologiche, Bologna, Italy; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; Laboratoire Français des Biotechnologies (LFB), Les Ulis, France; Influenza and Prion Disease Research Center, National Institute of Animal Health, Tsukuba, Japan

ABSTRACT

The genotype at polymorphic codon 129 of the PRNP gene has a profound influence on both phenotypic expression and prion strain susceptibility in humans. For example, while the most common sporadic Creutzfeldt-Jakob disease (CJD) subtype, sporadic CJD-MM1 (M1 strain), induces a single phenotype after experimental transmission regardless of the codon 129 genotype of the recipient animal, the phenotype elicited by sporadic CJD-VV2 (V2 strain), the second most common subtype, varies according to the host codon 129 genotype. In particular, the propagation of the V2 strain in codon 129 methionine homozygotes has been linked only to acquired forms of CJD such as plaque-type dura mater graft-associated CJD (dCJD), a subgroup of iatrogenic CJD with distinctive phenotypic features, but has never been observed in sporadic CJD cases. In the present report, we describe atypical CJD cases carrying codon 129 methionine homozygosity, in a neurosurgeon and in a patient with a medical history of neurosurgery without dural grafting, showing the distinctive phenotypic features and transmission properties of plaque-type dCJD. These findings raise the possibility that the two cases, previously thought to represent sporadic CJD, might actually represent acquired CJD caused by infection with the V2 strain. Thus, careful analyses of phenotypic features and transmission properties in atypical cases may be useful to distinguish acquired from sporadic cases of CJD.

IMPORTANCE

Susceptibility to and phenotypic expression of Creutzfeldt-Jakob disease (CJD) depend on both the prion strain and genotype at polymorphic codon 129 of the PRNP gene. For example, propagation of the second most common sporadic CJD strain (V2 strain) into codon 129 methionine homozygotes has been linked to plaque-type dura mater graft-associated CJD (dCJD), a subgroup of iatrogenic CJD with distinctive phenotypic features, but has never been observed in sporadic CJD. In the present report, we describe atypical CJD cases in a neurosurgeon and in a patient with a medical history of neurosurgery without dural grafting, showing the distinctive phenotypic features and transmission properties of plaque-type dCJD. These findings raise the possibility that the two cases, previously considered to represent sporadic CJD, might actually represent acquired CJD caused by infection with the V2 strain.

Creutzfeldt-Jakob disease (CJD) is a fatal transmissible neurodegenerative disease that may originate either from an apparently spontaneous generation of an abnormal isoform of prion protein (PrPSc) as in sporadic CJD (sCJD) and genetic CJD or from a PrPSc infection as in acquired CJD. Patients with sCJD show wide phenotypic heterogeneity, and their clinicopathological phenotype is determined by both the genotype (methionine [M] or valine [V]) at polymorphic codon 129 of the PRNP gene and the type (1 or 2) of PrPSc in the brain (1). PrPSc types 1 and 2 are distinguishable according to the size of the proteinase K-resistant core of the protein (21 and 19 kDa, respectively). Accordingly, sCJD is currently classified into six subtypes, i.e., MM1, MV1, VV1, MM2, MV2, and VV2 (1).

Phenotypic heterogeneity can also be recognized in transmission experiments using PrP-humanized knock-in mice, depending on both the inoculated CJD strain and the codon 129 genotype of the recipient animals (2–4). For example, sCJD-MM1 or sCJD-MV1 prions, representing the most common CJD strain (denoted strain M1 [4]), induce the same phenotype, i.e., diffuse synaptic-type PrP deposition and type 1 PrPSc accumulation resembling those observed in sCJD-MM1 or sCJD-MV1 patients, regardless of the mouse codon 129 genotype. In contrast, sCJD-VV2 or sCJD-MV2 prions, representing the second most common CJD strain (denoted strain V2 [4]), induce heterogeneous phenotypes with distinctive features depending on the codon 129 genotypes of the recipient animals. While animals carrying codon 129 valine homozygosity show plaque-type PrP deposition and type 2 PrPSc accumu-
TABLE 1 Patients’ histories and clinicopathological features of the atypical CJD cases

<table>
<thead>
<tr>
<th>Feature</th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
</tr>
<tr>
<td>Age at onset (yrs)</td>
<td>54</td>
<td>75</td>
</tr>
<tr>
<td>Occupational history</td>
<td>Neurosurgeon consulted on a case of CJD in which a myelogram was performed but not known to have participated in the procedure (7 yrs before onset)</td>
<td>Neurosurgery for cerebellar hemangioblastoma (14 yrs before onset)</td>
</tr>
<tr>
<td>Medical history^b</td>
<td>Surgical operations for perinephric abscess, inguinal herniorrhaphy, and removal of ureteric calculus (28 yrs, 8 yrs, and 32 mos before onset, respectively)</td>
<td></td>
</tr>
<tr>
<td>Initial symptoms^c</td>
<td>Abnormal sleep patterns, hallucinations, myoclonic twitching of the extremities, paresthesia of the toes, loss of vibration sense, gait disturbance</td>
<td>Drowsiness, gait disturbance</td>
</tr>
<tr>
<td>Duration of illness (mos)</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>PSWCs on EEG^d</td>
<td>Negative</td>
<td>Negative</td>
</tr>
<tr>
<td>PRNP gene^e</td>
<td>129M/M, 219E/E; no pathogenic mutations</td>
<td>129M/M, 219E/E; no pathogenic mutations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PrP deposition^f</th>
<th>Kuru plaques</th>
<th>Kuru plaques</th>
</tr>
</thead>
</table>

^a Details of the clinicopathological features of these patients have been reported elsewhere (10, 11). Underlined data were not described in the original reports and were obtained in the present study.

^b There was no medical history of the use of dura mater grafts, pituitary hormone, corneal transplants, or electroencephalogram (EEG) needles in either patient.

^c Case 1 had necrotizing cutaneous lesions with vasculitis in the lower extremities. A part of his initial symptoms might have been related to these lesions.

^d PSWCs on EEG, the presence of periodic sharp-wave complexes (PSWCs) in electroencephalogram (EEG) results, which is a characteristic of sCJD-MM1/MV1.

^e PRNP gene, the genotype at polymorphic codon 129 (methionine [M] or valine [V]) or codon 219 (glutamate [E] or lysine [K]) of the PRNP gene.

^f PrP deposition, the patterns of PrP deposition in the brain.

lation resembling those of human sCJD-VV2 cases, the animals carrying codon 129 methionine homozygosity develop numerous amyloid plaques (kuru plaques) and a unique PrPSc with electrophoretic mobility of about 20 kDa, which is intermediate in size between types 1 and 2 PrPSc and thus designated an intermediate type (type i) (5). It is noteworthy that the equivalent to the mouse phenotype with kuru plaques and type i PrPSc, reflecting transmission of the V2 sCJD strain to codon 129 methionine homozygotes, has been observed only in acquired prion diseases, especially in a subgroup of dura mater graft-associated iatrogenic CJD (plaque-type dCJD) cases in Japan, but not in sCJD cases (5–9). In addition, to pheno
typic expression, the codon 129 genotype may also influence prion strain susceptibility depending on the disease etiology, e.g., acquired versus sporadic. The finding that the plaque-type phenotypic association with codon 129 methionine homozygosity can be observed in iatrogenic dCJD but not in sCJD suggests that 129M PrPSc may be converted into type i PrPSc by the V2 sCJD strain in acquired CJD, while, in contrast, it would not be susceptible to a spontaneous conversion into the conformation of type i PrPSc.

Assuming that the combination of kuru plaques and type i PrPSc in CJD patients with codon 129 methionine homozygosity can be a reliable indication of transmission of the V2 sCJD strain, we have searched the literature for CJD cases reported as sCJD despite showing distinctive features resembling those of plaque-type dCJD. Furthermore, we have performed a transmission study to verify that the identified CJD cases were identical to plaque-type dCJD cases in transmission properties also.

MATERIALS AND METHODS

Ethics statement. Brain tissues were obtained at autopsy after receiving written informed consent for research use. Animal experiments were performed in strict accordance with the Regulations for Animal Experiments and Related Activities at Tohoku University and in accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions of the Ministry of Education, Culture, Sports, Science and Technology in Japan, notice no. 71. The protocol was approved by the Institutional Animal Care and Use Committee of Tohoku University.

Patients. We found two atypical CJD cases that showed widespread kuru plaques despite their 129M/M genotype. Details of these atypical CJD cases have been reported elsewhere (10, 11). In addition, clinically, genetically, and histopathologically proven sCJD and dCJD cases with the 129M/M genotype were also included in this study. The diagnosis of CJD, the PRNP genotype, and PrPSc type were confirmed by immunohistochemistry, Western blot analysis, and PRNP sequence analysis as described previously (12–14).

Transmission experiments. The production of knock-in mice expressing human PrP with the 129M/M or 129M/V or 129V/V genotype has been reported previously (15). Intracerebral inoculation was performed as described previously (5). The inoculated mice were sacrificed at a predefined clinical endpoint or died as a consequence of accident. One hemisphere of the brain was fixed in 10% buffered formalin for immunohistochemistry, and the other hemisphere was immediately frozen for Western blotting or serial passage. Incubation times are expressed as means ± standard errors of the means (SEM).

Immunohistochemistry. Formalin-fixed mouse brain tissues were treated with 60% formic acid for 1 h to inactivate the infectivity and were embedded in paraffin. Tissue sections were pretreated by hydrolytic autoclaving before PrP immunohistochemistry testing (12). PrP-N anti-PrP antiserum (12) was used as the primary antibody, and goat anti-rabbit immunoglobulin polyclonal antibody labeled with a peroxidase-conjugated dextran polymer, EnVision+ (Dako), was used as the secondary antibody. For morphometric analysis, at least four representative digital microscopy images of the cerebral cortices, white matter, basal ganglia, hippocampus, thalamus, and cerebellar cortices were obtained from each mouse. Data were collected from all diseased mice. These images were analyzed using ImageJ software (http://rsb.info.nih.gov/ij/). For quantification of PrP plaques, the number of plaques was manually counted on PrP-immunostained sections. Data are presented as means ± SEM. Differences between groups were analyzed by Student’s t test using JMP Pro software version 10.0 (SAS Institute Inc., USA). P values of <0.05 were considered significant.
Western blotting. PrPSc was obtained from cerebral cortex after tissue homogenization, collagenase digestion, and Sarkosyl-NaCl extraction (16). For deglycosylation of PrPSc, samples were digested with PNGaseF (New England BioLabs) (5). Protein samples were subjected to SDS-PAGE and Western blotting (14, 15). PrPSc type-specific polyclonal antibodies (designated Tohoku 1 [T1] or Tohoku 2 [T2]) (2) or anti-PrP monoclonal antibodies 3F4 (Signet) and #71 (17) were used as the primary antibodies. Anti-rabbit EnVision+ and anti-mouse EnVision+ were used as the secondary antibodies.

RESULTS

The clinical and neuropathological features of the two atypical cases of CJD are summarized in Table 1(10, 11, 18). One patient (case 1) was a neurosurgeon, whereas the other (case 2) had a medical history of neurosurgery without dura mater grafting. Both patients were homozygous for methionine at polymorphic codon 129 (129M/M) and homozygous for glutamate at polymorphic codon 219 of the PRNP gene, the latter being a rare glutamate/lysine polymorphism in Asian and Pacific populations which modulates the susceptibility to the CJD, similar to the codon 129 genotype (19). In addition, case 2 carried a 24-bp deletion in the octapeptide repeat region of the PRNP gene, which is a nonpathogenic polymorphism (20). It is noteworthy that both patients showed widespread PrP amyloid plaques despite their 129M/M genotype. Therefore, we examined the biochemical properties of PrPSc in their brain to test the possibility that these cases might have the intermediate type (type i) PrPSc similar to that seen with plaque-type dCJD. Western blot analysis of PrPSc revealed that the PrPSc in the two atypical CJD cases was smaller than the type 1 PrPSc (21 kDa) in sCJD-MM1 but was similar in size to the type i PrPSc (20 kDa) in plaque-type dCJD. (C) Western blot analysis of deglycosylated PrPSc fragments in the proteinase K-digested and PNGase F-treated brain homogenates using a monoclonal antibody, #71, which can detect carboxyl-terminal PrPSc fragments in addition to full-length PrPSc (17). The carboxyl-terminal PrPSc fragments in the atypical CJD cases (~10 kDa; black arrowhead) were smaller than those in sCJD-MM1 (~12 kDa; white arrowhead). sCJD-MM2 contained only trace amounts of the carboxyl-terminal PrPSc fragments that were identical in size to those in sCJD-MM1. (D) The carboxyl-terminal PrPSc fragments in the plaque-type dCJD (~10 kDa; black arrowhead) were also smaller than those in sCJD-MM1 or non-plaque-type dCJD (~12 kDa; white arrowhead). Plaque-type, plaque-type dCJD; Non-plaque-type, non-plaque-type dCJD.
caused by the transmission of sCJD-VV2 or sCJD-MV2 to individuals with the 129M/M genotype.

Next, we performed animal experiments using PrP-humanized knock-in mice carrying human PrP with the 129M/M, 129M/V, or 129V/V genotype to exclude the possibility that the atypical CJD cases might represent a very rare variation of the sCJD subgroups with the 129M/M genotype. Transmission study is still the gold standard in prion strain typing and can be a powerful tool to identify the causative origin of acquired prion diseases (15, 21). The transmissibility of the atypical CJD cases to the PrP-humanized mice was identical to that of plaque-type dCJD (Fig. 2A). In particular, although the incomparability of the 129 genotypes between host and inoculum usually results in a prolonged incubation period (5), the 129/V/V mice inoculated with brain homogenates from the atypical CJD cases or plaque-type dCJD showed incubation periods shorter than those of the other mouse lines. Moreover, the neuropathological and biochemical features in the inoculated mice were also identical between the atypical CJD and plaque-type dCJD. Briefly, after challenge with brain homogenates from the atypical CJD cases or plaque-type dCJD, the 129/M/M mice showed widespread PrP plaques in the cerebral cortices and thalamus, whereas the 129/V/V mice showed PrP plaques restricted to regions within the white matter (Fig. 2B and C). PrP-humanized mice inoculated with sCJD-MM1 material showed diffuse synaptic-type PrP deposition regardless of their codon 129 genotype. In Western blot analysis, after challenge with brain homogenates from the atypical CJD cases or plaque-type dCJD, the 129/M/M mice produced type i PrPSc (20 kDa), the 129/V/V mice produced type 2 PrPSc (19 kDa), and the 129/M/V mice produced both types 1 and 2 PrPSc (Fig. 2D and E). PrP-humanized mice inoculated with sCJD-MM1 material produced type 1 PrPSc (21 kDa) regardless of their codon 129 genotype. Since the transmission properties of plaque-type dCJD are similar to those of sCJD-VV2 or sCJD-MV2 (2, 3), these findings are in full agreement with a previous study showing neuropathological and biochemical similarities among nonhuman primates inoculated with brain homogenates from case 1, sCJD-VV2, or sCJD-MV2 (18). In summary, the transmission properties of the two atypical CJD cases were quite different from those of sCJD-MM1 and identical to those of plaque-type dCJD, sCJD-VV2, or sCJD-MV2, indicating that their causative origin might be sCJD-VV2 or sCJD-MV2.

We also examined the effects of serial passage on the transmission properties of case 2 (Fig. 3). The transmissibility, neuropathological features, and biochemical characteristics in each mouse line were identical to those in the primary passage. The codon 129 genotype of mice in the primary passage did not affect the transmission properties in the secondary passage. Thus, we confirmed that the characteristic transmission properties were maintained after serial passage through various codon 129 genotypes.

**DISCUSSION**

In the present report, we have shown that two CJD cases previously reported as sCJD shared neuropathological and biochemical features with plaque-type dCJD, namely, PRNP codon 129 methionine homozygosity (129M/M), widespread kuru plaques, and the intermediate type (type i) PrPSc accumulation in the brain. Furthermore, the transmission properties of the two CJD cases propagated in PrP-humanized mice were also identical to those of transmitted plaque-type dCJD. In particular, the 129/V/V mice showed the highest susceptibility to inocula from the two CJD cases despite the mismatched codon 129 genotypes and produced type 2 PrPSc, similarly to those observed in transmission studies of plaque-type dCJD (5). Moreover, these characteristic transmission properties were maintained after serial passage through various codon 129 genotypes. Taken together, the present results raise the possibility that these two CJD cases might have also been caused by transmission of sCJD-VV2 or sCJD-MV2 prions (V2 strain), as it is the case for plaque-type dCJD (9). Since transmission studies using PrP-humanized knock-in mice have been conducted so far on very limited numbers of typical iatrogenic CJD and sCJD cases, further analyses with larger series, including cases with atypical features, may be needed to generalize the implications of the present study. However, the main conclusion of our transmission experiments is also supported by a previous study showing identical neuropathological and biochemical features in nonhuman primates inoculated with brain homogenates from nonhuman primates inoculated with brain homogenates from...
case 2. Immunohistochemical analysis of PrP in the brains revealed that the case 2 in 129M/V, 674 in 129M/M-passaged case 2 in 129M/V, 691 inoculated mice) were as follows: 129M/M-passaged case 2 in 129M/M, 646 positive for PrP accumulation in immunohistochemical analysis/number of cerebral inoculation to the onset of disease and attack rates (number of mice codon 129 genotype of mice in the primary passage did not affect the trans-

transmission properties. Transmis-

passage were inoculated into additional knock-in mice of each genotype to

(A) Transmissibility to the PrP-humanized knock-in mice in the secondary passage of case 2. The brain homogenates of the affected mice in the primary passage were inoculated into additional knock-in mice of each genotype to examine the effects of serial passage on the transmission properties. Transmis-

sibility to each mouse line was identical to that in the primary passage. The
codon 129 genotype of mice in the primary passage did not affect the trans-

missibility in the secondary passage. The mean incubation periods from intra-
cerebral inoculation to the onset of disease and attack rates (number of mice positive for PrP accumulation in immunohistochemical analysis/number of inoculated mice) were as follows: 129M/M-passaged case 2 in 129M/M, 646 ± 10 days (10/10); 129M/M-passaged case 2 in 129M/V, 691 ± 16 days (7/7); 129M/M-passaged case 2 in 129V/V, 285 ± 8 days (8/8); 129M/V-passaged case 2 in 129M/M, 687 ± 43 days (9/9); 129V/V-passaged case 2 in 129M/V, 686 ± 28 days (7/8); 129M/V-passaged case 2 in 129V/V, 328 ± 6 days (9/9); 129V/V-passaged case 2 in 129M/M, 683 ± 57 days (6/7); 129V/V-passaged case 2 in 129M/V, 674 ± 6 days (7/9); and 129V/V-passaged case 2 in 129V/V, 292 ± 9 days (9/9). (B) Neuropathological features in the secondary passage of case 2. Immunohistochemical analysis of PrP in the brains revealed that the case 1 and sCJD-VV2 or from sCJD-MV2 which were clearly distinct from those of all animals inoculated from an unselected series of 55 cases of CJD-MM1 or sCJD-MV1 (18).

Iatrogenic transmission of CJD through neurosurgery has been reported in only 4 cases (22–25), and CJD transmission due to occupational exposure has not been recognized so far. In 2009, a Spanish pathologist developed CJD, and direct contact with infectious tissues during his professional activities was suspected to be the etiology of his disease because he had had a history of minor injuries during postmortem examinations (26). However, since his clinicopathological and biochemical features were indistinguishable from those of sCJD, the cause of his disease has remained undetermined. In contrast, our case 1, a neurosurgeon, showed distinctive phenotype and transmission properties that have been linked only to acquired CJD caused by infection with the V2 sCJD strain. The most plausible explanation for his disease etiology may be infection through occupational exposure over a period of many decades in which he had operated upon multiple patients with CJD. Furthermore, the other patient in the present study (case 2), who also showed distinctive phenotype and transmission properties similar to those of plaque-type dCJD, had a medical history of neurosurgery without dura mater grafting, suggesting that she might have also been infected through cross-contamination from operative instruments. During the period 1999 to 2008, the Japanese CJD Surveillance registry listed 6 of 760 sCJD patients who had undergone neurosurgery after the onset but before the diagnosis of sCJD (27). Although none of the individuals exposed to possibly contaminated instruments has developed CJD (as of September 2014), the ensemble of these observations suggests that the potential risk of iatrogenic transmission via neurosurgical procedures may be greater than is presently appreciated.

On the basis of the findings from the present study, together with data from previous studies (2, 3, 5), we propose the neu-

ropathological and biochemical criteria that may help distinguish acquired CJD caused by transmission of the V2 sCJD strain to individuals with the 129M/M genotype, here denoted acquired CJD-MMiK (the 129 M/M genotype, type i PrPSc, and kuru plaques), from sporadic CJD. Since widespread kuru plaques have also been reported in pituitary hormone-associated iatrogenic CJD cases with the 129M/M genotype (28, 29), the type of PrPSc in these cases needs to be examined in the future. In addition to these neuropathological and biochemical clues, clinical features of acquired CJD-MMiK, such as slow progression of disease and absence or late occurrence of periodic sharp-wave complexes on electroencephalogram, may also be distinctive as revealed by a comprehensive analysis of plaque-type dCJD (6, 7). Moreover, the experimental trans-

129M/M mice showed widespread PrP plaques in the cerebral cortices, whereas the 129V/V mice showed PrP plaques in the white matter (arrowheads) similar to those in the primary passage. The codon 129 genotype of mice in the primary passage did not affect the neuropathological features in the secondary passage. Scale bar, 100 μm. (C) Biochemical features in secondary passage of case 2. Western blot analysis of PrPSc in the brains using the conventional 3F4 anti-PrP antibody, type 1/type i PrPSc-specific T1 antibody, or type 2 PrPSc-specific T2 antibody revealed that the biochemical characteristics in each mouse line were identical to those in the primary passage. The codon 129 genotype of mice in the primary passage did not affect the biochemical features in the secondary passage. 129M/M-passaged, 129M/M mouse-passaged case 2; 129M/V-passaged, 129M/V mouse-passaged case 2; 129V/V-passaged, 129V/V mouse-passaged case 2.
mission data of our study suggest that PrP-humanized mice are also useful to evaluate transmissibility properties of acquired CJD-MMiK even after serial passage through various codon 129 genotypes. The diagnostic approach outlined above would help to distinguish acquired CJD from sporadic cases in the future as well as aid retrospective studies to investigate acquired CJD cases overlooked in past examinations.

Several issues remain to be addressed, the first of which is the potential for instrument cross-contamination of patients subjected to subsequent operations. Therefore, improvement of case recognition and ascertainment of the medical records of CJD patients are our future tasks. Second, it is uncertain whether the current decontamination/disinfection procedures are effective against all CJD strains, including the V2 sCJD strain that can cause acquired CJD-MMiK. The current procedures were developed using scapie and CJD isolates before genotyping became possible (30–32). However, different prion strains may show different susceptibilities to the decontamination procedures (33, 34). Therefore, the efficacy of the current decontamination procedures needs to be tested on the entire spectrum of CJD strains. Finally, the findings presented in this report have potential implications for the etiological classification of CJD, namely, the distinction between acquired and sporadic CJD. Indeed, while the detection of acquired CJD-MMiK cases may be facilitated by their distinctive neuropathological and biochemical features, this subgroup may account for only a minority of total acquired CJD cases. This is because the combined incidence rates of sCJD-VV2 and sCJD-MV2, the origins of acquired CJD-MMiK, are only 26% in European countries and the United States (35) and 3.2% in Japan (8) among total sCJD cases. In addition, the frequencies of the 129M/M genotype in the general population are 37% in European countries and the United States (1) and 92% in Japan (36). Therefore, the theoretical probabilities of occurrence of acquired CJD-MMiK, i.e., transmission of the V2 sCJD strain to individuals with the 129M/M genotype, are only 9.6% (= 26% × 37%) and 2.9% (= 3.2% × 92%) of the total proportions of possible iatrogenic transmission, respectively. The other acquired CJD cases, i.e., the other combinations of source of infection and host codon 129 genotype, may be indistinguishable from sCJD cases with respect to neuropathological and biochemical features, as suggested by animal experiments (2, 3). These facts raise the disturbing possibility that more acquired CJD cases may remain unrecognized.

In conclusion, we identified two CJD cases that were reported as sCJD but that showed distinctive phenotypic features and transmission properties of plaque-type dCJD, which is caused by the transmission of V2 sCJD strain to individuals with the 129M/M genotype. The available clinical records of the two cases did not show the direct evidence of exposure to prion-contaminated neurosurgical instruments, and other potential routes of infection could not be rigorously investigated because of the insufficient clinical information. Nevertheless, the results of the present study may indicate the need to reconsider the potential risk of CJD transmission via occupational exposure as well as neurosurgery. Further investigation of acquired CJD cases and their routes of infections may help to identify novel risk factors of CJD transmission in the future.

ACKNOWLEDGMENTS

This study was supported by Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan (A.K. and S.M.), Grants-in-Aid for Scientific Research from JSPS (A.K. and T.K.), a grant from MEXT for the Joint Research Program of the Research Center for Zoonosis Control, Hokkaido University (T.K.), and a Grant-in-Aid for Scientific Research on Innovative Areas (Brain Protein Aging and Dementia Control) from MEXT (T.K.). Research for development of decontamination/disinfection procedures against various sCJD subgroups has been supported by a Grant-in-Aid from the Research Committee of Surveillance and Infection Control of Prion Disease, the Ministry of Health, Labor and Welfare of Japan (T.K.).

We thank Y. Ishikawa, H. Kudo, M. Yamamoto, and A. Yamazaki for their excellent technical assistance and B. Bell for critical reviews of the manuscript.

REFERENCES


